Category Archives: Parkinson’s Treatment

AUGUSTA, Ga. (WJBF) Dr. John Morgan is the director of the Movement and Memory Disorder Program at the Medical College of Georgia at Augusta University. Continue reading →

New Jersey has one of the highest rates in the nation of Parkinson's disease a neuro-degenerative disorder, typically affecting residents between ages 60 and 70 years old. Continue reading →

One of the key goals of the Weill NeuroHub is to explore the brains circuitry using the most powerful MRIs available, developed at UC Berkeley. With a $106 million gift from the Weill Family Foundation, UC Berkeley (Berkeley), UC San Francisco (UCSF) and the University of Washington (the UW) have launched the Weill Neurohub, an innovative research network that will forge and nurture new collaborations between neuroscientists and researchers working in an array of other disciplinesincluding engineering, computer science, physics, chemistry, and mathematicsto speed the development of new therapies for diseases and disorders that affect the brain and nervous system Continue reading →

SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), today announced it will host a live webcast of its investor event following the late-breaking oral presentation of the Phase 3 HARMONY results evaluating pimavanserin as a treatment for dementia-related psychosis at the upcoming 12th Clinical Trials on Alzheimers Disease (CTAD) Meeting. Webcast Details The live webcast will include a presentation of the results by ACADIA management followed by a KOL panel discussion with live Q&A. Continue reading →

SAN DIEGO, Nov. 12, 2019 /PRNewswire/ --Neurocrine Biosciences, Inc Continue reading →

Editors from The American Journal of Managed Care (AJMC) spoke with Sanford Auerbach, MD, to discuss considerations for treating older adults with insomnia. Continue reading →

Initiated two Phase 2 studies of NYX-2925 in chronic pain conditions On track to have four Phase 2 studies ongoing by year end across pipeline of CNS product candidates Conference call today at 5:00 p.m. Continue reading →

Parkinsons disease currently affects over 10 million people worldwide, and in the United States approximately 60,000 people are diagnosed with the disease each year. It is a disease in which the brain cells, or neurons, that produce dopamine progressively die off over time. Continue reading →

Jobs are on the chopping block at Acorda Therapeutics and Alkermes as each company works to cut costs and stay alive. Acorda will lay off about one-quarter of its employees, while Alkermes will cut 160 jobs. Acorda will cut about 25% of its staffers, starting immediately,the company said Wednesday Continue reading →

We all are aware of how the Arthritis Association is requesting the government to fund CBD research because several patients suffering from the illness have discovered relief. Likewise in a move that might be a big breakthrough in the field of medicine, patients suffering from Parkinsons disease are all set to become a part of a clinical trial. The research will aim at finding out how CBD can be effective and safe to treat symptoms like hallucinations and delusions Continue reading →